Boehringer Ingelheim and Lilly commence Trajenta study

Boehringer Ingelheim and Lilly have begun a new trial to further support the clinical profile of their type 2 diabetes therapy Trajenta.

The first patient has been enrolled in the Carmelina trial, which will investigate the impact of the once-daily dipeptidyl peptidase-4 inhibitor on cardiovascular and renal microvascular outcomes among diabetic adults who are at risk of cardiovascular and renal events.

It will involve more than 8,000 adults in 24 countries at over 500 sites around the world, with the study expected to be completed in 2018.

Diabetes has been identified as a major risk factor for cardiovascular disease, as well as a leading cause of chronic renal failure.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "The initiation of this trial reinforces our ongoing commitment to evaluate the efficacy and safety of linagliptin, ensuring that treating physicians are provided with all required information."

This comes after the firms launched another study called Marlina earlier this year to assess the glycaemic efficacy and safety of Trajenta among patients with type 2 diabetes and prevalent albuminuria.